Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cardiovascular protection following empagliflozin therapy is not entirely attributable to the glucose lowering effect. Increased hematocrit might influence the shear stress that is the main force acting on the endothelium, regulating its anti-atherogenic function. OBJECTIVE: We designed the study with the aim of investigating the effect of empagliflozin on blood viscosity and shear stress in the carotid arteries. A secondary endpoint was the effect of empagliflozin on carotid artery wall thickness. METHODS: The study was a non-randomized, open, prospective cohort study including 35 type 2 diabetic outpatients who were offered empagliflozin or incretin-based therapy (7 liraglutide, 8 sitagliptin) in combination with insulin and metformin. Blood viscosity, shear stress and carotid wall thickness were measured at baseline and at 1 and 3 months of treatment. Blood viscosity was measured with a viscometer, and shear stress was calculated using a validated formula. Intima-media thickness (IMT) of the carotid artery was detected by ultrasound and was measured with dedicated software. RESULTS: Blood viscosity (4.87 ± 0.57 vs 5.32 ± 0.66 cP, p < 0.02) and shear stress significantly increased in the Empagliflozin group while no change was detected in the Control group (4.66 ± 0.56 vs 4.98 ± 0.73 cP, p = NS). IMT significantly decreased in the Empagliflozin group after 1 and 3 months (baseline: 831 ± 156, 1-month 793 ± 150, 3-month 766 ± 127 μm; p < 0.0001), while in the liraglutide group, IMT significantly decreased only after 3 months (baseline 879 ± 120; 1-month 861 ± 163; 3-month 802 ± 114 μm; p < 0.001). In the sitagliptin group, IMT remained almost unchanged (baseline 901 ± 135; 1-month 902 ± 129; 3-month 880 ± 140 μm; p = NS). CONCLUSIONS: This study is the first to describe a direct effect of empagliflozin on blood viscosity and wall shear stress. Furthermore, IMT was markedly reduced early on in the Empagliflozin group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In a previous study including diabetic patients, a three-month treatment with empagliflozin resulted in a significant regression of complex intima media thickness (cIMT) by 7.9%; p < 0.0001. Interestingly, this effect was significant just after one month of empagliflozin therapy [34].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
O'Leary, D. H., Polak, J. F., Kronmal, R. A., Manolio, T. A., Burke, G. L., & Wolfson, S. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400103 · Cited by 4,685
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740 · cited 1×
“mediators of the reduction in risk of CV death with empagliflozin vs placebo [27].”
BackgroundSodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator.
Cooke, J. P., Rossitch, E., Andon, N. A., Loscalzo, J., & Dzau, V. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115481 · Cited by 533
Chilton, R., Tikkanen, I., Cannon, C. P., Crowe, S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12572 · Cited by 507
Lytvyn, Y., Bjornstad, P., Udell, J. A., Lovshin, J. A., & Cherney, D. Z. I. (2017) · Circulation · doi:10.1161/circulationaha.117.030012 · Cited by 459 · cited 1×
“SGLT2 inhibitors have recently been demonstrated to markedly reduce cardiovascular mortality with highly significant reduction in admissions for heart failure and end-stage renal disease, despite modest effects on long-term glycemic control [1, 2, 6].”
Background
Research works printed but not linked: 2
- Standard Italiani per la cura del Diabete Mellito 2016. vol. 5, p. 91–117. http://www.standarditaliani.it . Accessed 20 June 2016.
- Schou M, Gullestad L, Fitchett D, Zinman B, Inzucchi SE, Hehnke U, von Eynatten M, George J, Johansen OE, Wanner C. Empagliflozin exerts short- and long-term effects on plasma volume in patients with type 2 diabetes: insight from EMPA-REG OUTCOME. Circulation. 2017;136:A15997.
Cited by
Li, C., Zhang, J., Xue, M., Li, X., Han, F., Liu, X., Xu, L., Lu, Y., Cheng, Y., Li, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0816-2 · Cited by 580
Neuroprotective effect of SGLT2 inhibitors.
Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304
“CIMT Regression n/a n/a Yes [33] Yes [34] /”
BackgroundBosch, A., Ott, C., Jung, S., Striepe, K., Karg, M. V., Kannenkeril, D., Dienemann, T., & Schmieder, R. E. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0839-8 · Cited by 125
Fuchigami, A., Shigiyama, F., Kitazawa, T., Okada, Y., Ichijo, T., Higa, M., Hiyoshi, T., Inoue, I., Iso, K., Yoshii, H., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0977-z · Cited by 128
Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches
Khan, A. W., & Jandeleit-Dahm, K. A. M. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-024-01115-w · Cited by 106
“In addition, intima–media thickness was markedly decreased early after initiation of empagliflozin treatment compared with incretin-based therapy 15 .”
Metadata
- Authors
- Irace, C., Casciaro, F., Scavelli, F. B., Oliverio, R., Cutruzzolà, A., Cortese, C., & Gnasso, A.
- Affiliations
- Magna Graecia University (IT)
- University of Rome Tor Vergata (IT)
- Corresponding author
- Irace, Concetta
- Venue
- Cardiovascular Diabetology
- Published
- 2018-04-09
- Volume
- 17
- Issue
- 1
- Pages
- 52-52
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC5891980
- OpenAlex
- W2799739525
- Cited by
- 74
- References
- 42
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 9 · 2023: 14 · 2022: 9 · 2021: 11 · 2020: 5 · 2019: 10 · 2018: 1
- FWCI
- 5.37
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hematology › Blood properties and coagulation
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, blood viscosity, wall shear stress, type 2 diabetes, carotid intima-media thickness, incretin-based therapy, liraglutide, sitagliptin, endothelial function, atherosclerosis, cardioprotection, hematocrit, carotid artery wall thickness, SGLT2 inhibitors
- MeSH terms
- Sitagliptin Phosphate, Liraglutide, Sodium-Glucose Transporter 2 Inhibitors, Aged, Benzhydryl Compounds, Blood Viscosity, Diabetes Mellitus, Type 2, Female, Glucosides, Humans, Male, Middle Aged, Prospective Studies, Regional Blood Flow, Stress, Mechanical, Time Factors, Treatment Outcome, Carotid Artery, Common, Incretins, Carotid Intima-Media Thickness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy. https://app.cochat.ai/papers/10.1186/s12933-018-0695-y
- The paper
- Irace, C., Casciaro, F., Scavelli, F. B., Oliverio, R., Cutruzzolà, A., Cortese, C., & Gnasso, A. (2018). Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy. Cardiovascular Diabetology. https://doi.org/10.1186/s12933-018-0695-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
